Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.

MLA

Molina, Rafael, et al. “Pro-Gastrin-Releasing Peptide (ProGRP) in Patients with Benign and Malignant Diseases: Comparison with CEA, SCC, CYFRA 21-1 and NSE in Patients with Lung Cancer.” Anticancer Research, vol. 25, no. 3A, May 2005, pp. 1773–78. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=16033098&authtype=sso&custid=ns315887.

APA

Molina, R., Auge, J. M., Filella, X., Viñolas, N., Alicarte, J., Domingo, J. M., & Ballesta, A. M. (2005). Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer. Anticancer Research, 25(3A), 1773–1778.

Chicago

Molina, Rafael, Jose M Auge, Xavier Filella, Nuria Viñolas, Julian Alicarte, Jose M Domingo, and Antonio M Ballesta. 2005. “Pro-Gastrin-Releasing Peptide (ProGRP) in Patients with Benign and Malignant Diseases: Comparison with CEA, SCC, CYFRA 21-1 and NSE in Patients with Lung Cancer.” Anticancer Research 25 (3A): 1773–78. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=16033098&authtype=sso&custid=ns315887.